TrialKidney international2020

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.

Erik J M van Bommel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.